Global Small Molecule Drug CDMO Market Growth (Status and Outlook) 2023-2029

Global Small Molecule Drug CDMO Market Growth (Status and Outlook) 2023-2029

The global Small Molecule Drug CDMO market size is projected to grow from US$ 27230 million in 2022 to US$ 41280 million in 2029; it is expected to grow at a CAGR of 6.1% from 2023 to 2029.

United States market for Small Molecule Drug CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Small Molecule Drug CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Small Molecule Drug CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Small Molecule Drug CDMO players cover Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried and FUJIFILM Diosynth Biotechnologies, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.

LPI (LP Information)' newest research report, the “Small Molecule Drug CDMO Industry Forecast” looks at past sales and reviews total world Small Molecule Drug CDMO sales in 2022, providing a comprehensive analysis by region and market sector of projected Small Molecule Drug CDMO sales for 2023 through 2029. With Small Molecule Drug CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Small Molecule Drug CDMO industry.

This Insight Report provides a comprehensive analysis of the global Small Molecule Drug CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Small Molecule Drug CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Small Molecule Drug CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Small Molecule Drug CDMO and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Small Molecule Drug CDMO.

This report presents a comprehensive overview, market shares, and growth opportunities of Small Molecule Drug CDMO market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
FDF CDMO
Packaging CDMO
Clinical CDMO

Segmentation by application
Pharmaceutical Company
Biotechnology Company
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton



Please note: The report will take approximately 2 business days to prepare and deliver.